Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2025.12.18.694395

Non-canonical TERT function mitigates adipose tissue inflammation in obesity by modulating stem cell-macrophage communication and macrophage states

Braud, L.·Ninni, A.·Miranda, A. M. A.·Baudelet, E.·Vernerey, J.·Villaverde, M.·Sciarretta, F.·Bernabe, M.·Girondier, L.·Elia, I.·Gil, J.·Audebert, S.·Brondello, J.-M.·Lachaud, C.·Scott, W.·Lettieri.Barbato, D.·Geli, V.
View original source ↗Export metadata ↓

Abstract

Background and aimsObesity drives adipose tissue (AT) expansion and chronic inflammation, leading to metabolic dysfunction through adipocyte hypertrophy, impaired ASPC differentiation, immune infiltration, and fibrosis. Stromal vascular remodeling prominently features expansion of Gdf15- and Trem2-expressing lipid-associated macrophages (LAMs), which respond to adipocyte stress and act as lipid scavengers to buffer excess lipids released by adipocytes. Here, we examined macrophage reprogramming in p21+/Tert and p21+/TertCi mice, which express active TERT or its catalytically inactive TERTCi mutant from the endogenous Cdkn1a promoter. ResultsFollowing HFD exposure, conditional expression of TERT or TERTCi resulted in a pronounced downregulation of p21 in macrophage subsets, accompanied by a reduction in AT inflammation. Notably, TERT and TERTCi expression reshaped the adipose-tissue macrophage (ATM) landscape depleting Trem2+ and Gdf15+ LAMs while preserving resident macrophages. This shift was accompanied by marked suppression of the Trem2 transcriptional program and down-regulation of PPAR-{gamma} and NR1H3 in LAMs and by impaired ASPC-LAM signaling pathways that normally drive LAM recruitment and activation. Proteomic profiling further showed that p21+/Tert ASPCs secreted markedly higher levels of proteins associated with non-conventional secretion, while extracellular matrix-associated factors and cytokines/chemokines including key mediators of ASPC-LAM communication such as Ccl2, C3, and Csf1 were substantially reduced. However, only p21+/Tert mice, and not p21+/TertCi mice, exhibited significant metabolic improvements, indicating that macrophage remodeling alone is insufficient to restore systemic metabolic function. Consistent with this, enhanced ASPC expansion and differentiation, supporting improved adipose-tissue remodeling, was observed exclusively in p21+/Tert obese mice. ConclusionsTERT remodels adipose tissue immunity independently of its enzymatic activity, and TERT-driven reprogramming of the ASPC secretome may emerge as a promising strategy to combat obesity-related metabolic dysfunction. HighlightsO_LIConditional expression of TERT or catalytically inactive TERTCi results in the depletion Trem2+ and Gdf15+ LAMs while preserving resident macrophages C_LIO_LITERT and TERTCi expression impairs ASPC-adipocyte/LAM communication pathways that normally drive LAM recruitment and activation. C_LIO_LIIn vitro, TERT conditional expression in ASPCs promotes non-conventional protein secretion and reduces the secretion of key mediators of ASPC-LAM communication C_LIO_LIOnly p21+/Tert mice, and not p21+/TertCi mice, exhibited enhanced ASPC expansion, improved adipose-tissue remodeling, and systemic metabolic benefits, demonstrating that macrophage remodeling alone is insufficient to restore metabolic function. C_LI

Explore related subjects

physiologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Braud, L., Ninni, A., Miranda, A. M. A., Baudelet, E., Vernerey, J., Villaverde, M., Sciarretta, F., Bernabe, M., Girondier, L., Elia, I., Gil, J., Audebert, S., Brondello, J.-M., Lachaud, C., Scott, W., Lettieri.Barbato, D., Geli, V.. 2025-12-18. Non-canonical TERT function mitigates adipose tissue inflammation in obesity by modulating stem cell-macrophage communication and macrophage states. https://doi.org/10.64898/2025.12.18.694395

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Selective activation of estrogen receptors modulates electrical activity and insulin secretion in human EndoC-βH1 cells

Estrogen receptors (ERs), ER and ER{beta} have important roles in the physiology of the endocrine pancreas in animal models, but the effects of ER activation on insulin-secreting human cells are still poorly understood. Here, we investigated the role of ER and ER{beta} as modulators of electrical activity and insulin secretion in the insulin-secreting human cell line EndoC-{beta}H1. Immunocytochemical analysis revealed a widespread cellular distribution of ER, while ER{beta} was predominantly localized outside the nucleus. We observed that both estradiol (E2) and the ER{beta} agonist diarylpropionitrile (DPN) led to a decrease in insulin secretion in the absence of stimulatory glucose concentrations, without affecting insulin content. Patch-clamp experiments revealed that a 48-hour treatment with either the ER agonist PPT or DPN resulted in depolarization of the resting membrane potential, increased action potential firing frequency, and altered the action potential waveform in EndoC-{beta}H1 cells. PPT increased voltage-dependent Ca2+ channel currents, while DPN reduced K+ and Na+ currents. These results suggest that activation of ER and ER{beta} modulates beta-cell electrical activity through distinct pathways involving ion channels. The effects of E2, PPT, and DPN were not caused by altered expression levels of ion channel genes after 48 hours of treatment. This suggests that these receptors act extranuclearly without affecting gene expression. Together, our findings demonstrate that selective activation of ER and ER{beta} modulates beta-cell excitability through distinct electrophysiological mechanisms and that E2 and DPN reduce basal insulin secretion in human EndoC-{beta}H1 cells. These results support ER and ER{beta} as potential targets for modulating human pancreatic beta-cell function.

physiology↗
bioRxiv2026

Body weight modifies the efficacy of lifespan-extending interventions in ad libitum-fed mice

Geroprotective interventions are often assessed by extension of lifespan in ad libitum-fed mice. Increased lifespan could therefore reflect rescue of adverse phenotypes of unhealthy controls. We analysed body weight and survival for 33,780 mice in the Interventions Testing Program (ITP) to test whether treatment effects varied with body weight. In males, each added standard deviation of attained adult weight made treatment 6% more favourable (HR 0.94), more apparent for interventions that lowered body weight (HR 0.90). Median lifespan increase rose from 6.2% in mice in the lightest quartile to 20.2% in the heaviest pre-dosing weight quartile among those experiments, mainly because control survival declined more steeply with weight than that of the intervention group. The effect of body weight was consistent across 13 of 14 compounds and reflected weight attained during adulthood rather than in early life. Weight-dependence of intervention effects was weak in ITP females, possibly because median survival of controls exceeded that of every sampled non-ITP female control group. Amelioration of weight-associated risk is therefore implicated as a major contributor to lifespan increases relative to heavy, short-lived controls. The geroprotective effects of these interventions may thus be less apparent in metabolically healthier mice or humans.

physiology↗
bioRxiv2026

Single-nucleus analysis reveals renal STAT1/CEBPB signaling as a modifiable relay of proinflammatory FGF23 effects in diabetic kidney disease

Background Circulating fibroblast growth factor 23 (FGF23) rises dramatically in chronic kidney disease, particularly in diabetic kidney disease (DKD). At high concentrations, and with declining Klotho, FGF23 has been linked to renal inflammation. The cell types and transcriptional programs mediating these off-target actions remain undefined. We asked whether the diseased kidney responds to FGF23 differently from the healthy kidney, and whether any disease-specific response could be targeted. Methods Male and female DBA/2J mice received streptozotocin or vehicle to induce DKD. On day 56, mice received a single dose intravenous injection of FGF23 (0.3 g) or vehicle, with tissue collected 1 h later for single-nucleus RNA sequencing, differential expression and regulon (inferred transcription factor activity) analysis. Candidate pathways were tested in precision-cut kidney slices using the CEBPB inhibitor ST-101. Results Streptozotocin-treated male mice developed early DKD with a 6-fold increase in urinary albumin/creatinine ratio and 50% higher blood urea nitrogen with preserved glomerular filtration rate. All major renal cell types were annotated. Canonical FGF23 signaling was intact in disease, with segment-specific target induction conserved in both conditions (e.g. Cyp24a1 in PT-S1 and DCT1). Superimposed on this were disease-restricted responses, including Wsb1 in DCT1 and Pdk4 in PT-S2, PST, DCT1 and DCT2. Regulon analysis revealed DKD-specific induction of CEBPB regulon activity by FGF23 across all analyzed tubular segments, and of STAT1 in several segments. Pre-treatment with a CEBPB inhibitor suppressed CEBPB activity, downstream NF-KB and pro-inflammatory gene sets, and immune-like cell abundance in diseased slices. Conclusion In the diabetic kidney, FGF23 engages a STAT1-CEBPB-NF-{kappa}B axis absent from healthy kidney and extending beyond its canonical Klotho-dependent target segments, identifying CEBPB as a potential treatment target for FGF23's pathological inflammatory actions.

physiology↗